<DOC>
	<DOCNO>NCT00176605</DOCNO>
	<brief_summary>Based data support use cyclophosphamide etoposide single agent combination Phase I study show acceptable toxicity chronic dose regimen , propose Phase II clinical trial . This protocol establish model test hypothesis use etoposide cyclophosphamide early course prostate cancer progression , few tumor cell present , great anti-tumor activity . We plan treat patient stage D0 prostate cancer assess toxicity anti-tumor activity .</brief_summary>
	<brief_title>Phase II Metronomic Dosing , Etoposide , Cyclophosphamide , D0 Prostate Cancer</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<criteria>Inclusion Criteria Patients histologically proven prostate cancer tumor limit prostate ( include seminal vesicle involvement , provide visible disease surgically remove ) complete local therapy rise PSA value , define Section 5.1.5 . Prior androgen ablation therapy allow long patient complete therapy least 1 year prior entry study . The patient must fully recover therapy must demonstrate progression androgen ablation therapy . Primary treatment prostate ( surgery and/or radiation ) must complete least 3 month prior entry study patient must fully recover therapy . Patients must negative CT chest , abdomen pelvis bone scan . The scan must complete within 4 week prior date start therapy . PSA value patient enrol must &gt; 2 ng/ml double time £ 12 month . PSA value &gt; 2 ng/ml must document two measurement least four week apart . The final PSA measurement study entry must obtain within one week prior therapy . This consider baseline PSA . ( Note : The website http : //www.mskcc.org/mskcc/html/10088.cfm may use access prostate normogram calculator . ) The following lab value must obtain within 4 week prior therapy : ANC ≥1500/mm³ , Hemoglobin ≥ 10 g/dl Platelet count ≥ 100,000/mm³ Serum creatinine ≤ 1.5 mg/dL Total bilirubin ≤ 1.5 mg/dL Liver function test ( SGOT , SGPT ) ≤ 1.5 time upper limit institution 's normal range . Men ≥ 18 year age . An estimated life expectancy least 6 month . ECOG performance status ≤ 2 . Able give inform , write consent . Men must consent use effective contraception ( barrier method latex condom ) treatment 4 week discontinuation treatment . Exclusion Criteria Patients active infection know infection HIV ( HIV test perform part study ) . Any coexist medical condition include uncontrolled cardiac , hepatic , renal psychiatric disease define ³ Grade 3 ( CTCAE Version 3 ) . Concurrent use investigational agent . Patients previously receive 2 month therapy agent use study . PSA value &lt; 2 ng/ml . Prior chemotherapy past 5 year . Use androgen ablation therapy within 1 year , history progression androgen ablation therapy .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2014</verification_date>
	<keyword>prostate cancer</keyword>
	<keyword>recurrent prostate cancer</keyword>
	<keyword>stage IV prostate cancer</keyword>
</DOC>